Arcutis Biotherapeutics Inc (NASDAQ: ARQT) is 187.00% higher on its value in year-to-date trading and has touched a low of $1.76 and a high of $15.40 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ARQT stock was last observed hovering at around $9.26 in the last trading session, with the day’s gains setting it 0.01%.
Currently trading at $9.27, the stock is -11.57% and 17.21% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.77 million and changing 0.11% at the moment leaves the stock 44.20% off its SMA200. ARQT registered -9.38% loss for a year compared to 6-month gain of 60.38%. The firm has a 50-day simple moving average (SMA 50) of $16.76 and a 200-day simple moving average (SMA200) of -$4.39.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -4.33% loss in the last 1 month and extending the period to 3 months gives it a 213.18%, and is -5.98% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.02% over the week and 9.99% over the month.
Arcutis Biotherapeutics Inc (ARQT) has around 296 employees, a market worth around $897.43M and $3.69M in sales. Profit margin for the company is -8449.76%. Distance from 52-week low is 426.70% and -39.81% from its 52-week high. The company has generated returns on investments over the last 12 months (-105.99%).
Arcutis Biotherapeutics Inc quarterly earnings per share for the current quarter are estimated at -$0.74 with sales reaching $13.94M over the same period.The EPS is expected to grow by 34.20% this year, but quarterly earnings will post 65.50% year-over-year. Quarterly sales are estimated to grow 401.30% in year-over-year returns.
Arcutis Biotherapeutics Inc (ARQT) Top Institutional Holders
182 institutions hold shares in Arcutis Biotherapeutics Inc (ARQT), with institutional investors hold 98.40% of the company’s shares. The shares outstanding are 96.79M, and float is at 88.37M with Short Float at 17.86%. Institutions hold 96.04% of the Float.
The top institutional shareholder in the company is Jennison Associates LLC with over 9.07 million shares valued at $84.04 million. The investor’s holdings represent 9.36% of the ARQT Shares outstanding. As of Dec 30, 2023, the second largest holder is Frazier Life Sciences Management, L.P. with 8.76 million shares valued at $81.24 million to account for 9.05% of the shares outstanding. The other top investors are Suvretta Capital Management, LLC which holds 8.47 million shares representing 8.75% and valued at over $78.55 million, while Rubric Capital Management LP holds 6.86% of the shares totaling 6.64 million with a market value of $61.59 million.
Arcutis Biotherapeutics Inc (ARQT) Insider Activity
The most recent transaction is an insider purchase by Heron Patrick J,the company’sDirector. SEC filings show that Heron Patrick J bought 21,052 shares of the company’s common stock on Mar 04 ’24 at a price of $9.50 per share for a total of $0.2 million. Following the purchase, the insider now owns 8.79 million shares.
Arcutis Biotherapeutics Inc disclosed in a document filed with the SEC on Mar 04 ’24 that Watanabe Todd Franklinsold a total of 14,903 shares of the company’s common stock. The trade occurred on Mar 04 ’24 and was made at $11.12 per share for $0.17 million. Following the transaction, the insider now directly holds 0.87 million shares of the ARQT stock.
Still, SEC filings show that on Mar 04 ’24, Burnett Patrick () disposed off 4,782 shares at an average price of $11.12 for $53182.0. The insider now directly holds 269,300 shares of Arcutis Biotherapeutics Inc (ARQT).
